COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Dr. Robert Melamede, President and CEO of Cannabis Science (CBIS), announced today that Roscoe Moore, DVM, PhD, MPH has been appointed to the Scientific Advisory Board.
About Dr Roscoe M. Moore Jr., DVM, MPH, Ph.D.,
Senior
Scientific Advisory Board Member, CBIS
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA) along with the positions in the US Public Health Service, and most recently, the Office of the US Secretary of Health and Human Services.
Dr. Moore was named a Senior Fellow at the Potomic Institute in June 2003. He is currently the CEO and Vice Chairman of the Global Flu Consortium. As both a distinguished epidemiologist and veterinarian, Dr. Moore is particularly well positioned to help guide business planning and response to the Avian Flu. Dr. Moore brings to the Institute, deep experience and leadership through service that includes responsibilities as former Assistant United States Surgeon General, and as Rear Admiral in the U.S. Public Health Service. One of the world-renowned experts in epidemiology, Dr. Moore has been involved in the surveillance of emerging and re-emerging diseases worldwide as well as bioterrorism issues, and the safety of bioengineered foods.
Dr. Moore was the top-ranking veterinarian in all of the Uniformed Services, and served as the Associate Director for Development Support and African Affairs for the Department of Health and Human Services (HHS). In this capacity, Dr. Moore was the principal liaison between HHS and ministries of health for 53 countries in Africa, focusing on developing infrastructure and technical support to deliver preventive and curative human health needs for the continent.
Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; he also has received an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues.
“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining the Cannabis Science Scientific Advisory Board as the company enters into further clinical development of a wide range of commercial clinical investigations. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to Cannabis Science. In addition to overseeing the development of CS-TATI-1, he will assist in our path towards human studies for HIV drug resistance and catabolic cachexia,” commented Dr Melamede. “Dr. Moore’s decision to join Cannabis Science's Scientific Advisory Board emphasizes the potential of phytocannabinod antiviral activity and our strong research and development efforts.”
CS-TATI-1 is in preclinical development intended to target HIV TAT, which is an important target for developing new HIV drugs, which are urgently needed. While there are currently 30 antiretroviral drugs on the market, increasing drug resistance to and toxicity from long term use of all existing medications. There is a high demand and need for new treatments to treat HIV drug resistance patients
Cannabis Science at AIDS 2012
AIDS 2012 is said to be the largest AIDS conference to date, with over 30,000 participants coming together from 200 different countries, Cannabis Science will be presenting at the World AIDS Institute’s Treatment Horizons satellite symposium on Cannabis Science’s HIV therapeutic research program based on the recent discovery by the Mount Sinai School of Medicine that phytocannabinoids inhibit a key HIV gene called TAT, which controls the virus’s ability to replicate.
Cannabis Science is also currently working with CBR International Corp. to develop a pre-IND application to the FDA that focuses on the use of CS-S/BCC-1 cannabinoid-based topical preparations for the treatment of basal and squamous cell carcinomas. CBR International’s Regulatory Strategy and Affairs Group are experienced in developing strategies for companies to proceed through various regulatory pathways to market in the United States and Europe. Their diverse team has the expertise in drugs, biologics and devices to efficiently navigate the regulatory approval process. They have Prepared and submitted over 100 INDs, IND, amendments, IDEs and Annual Reports to FDA. CBR has also Planned and participated in over 20 pre-IND/Pre-IDE meetings with FDA. As well, developed and implemented programs to prepare sponsors for Type A, B, and C meetings with FDA.
Cannabis Science released a press release dated June 5, 2012, titled “Cannabis Science Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development” which, is featured on the AIDS 2012 Reunion Website: http://www.aids2012reunion.org/
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.